Clinical Research Directory
Browse clinical research sites, groups, and studies.
This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
Sponsor: LTZ Therapeutics, Inc.
Summary
This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.
Official title: A Phase 1/1b, Muticenter Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
152
Start Date
2026-12
Completion Date
2031-12
Last Updated
2026-10-16
Healthy Volunteers
No
Interventions
LTZ-232
LTZ-232 will be administered intravenously every two weeks for up to 24 months unless treatment discontinuation criteria are met.
Locations (1)
HonorHealth Research Institute
Scottsdale, Arizona, United States